Safety and efficacy of early initiation of mineralocorticoid receptor antagonists in patients with worsening heart failure: a meta-analysis of randomized controlled trials

19 May 2025 (16:00 - 16:45)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Renzo Laborante

South General Hospital, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail

Effects of glucagon like peptide 1 receptor agonist initiation in patients with heart failure and reduced ejection fraction and implantable cardiac devices

Doctor P. Marques (Porto, PT)

Abstract Slides Video

Presentation thumbnail

Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study

Professor I. Gruev (Sofia, BG)

Abstract Slides Video

Presentation thumbnail

Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection

Doctor D. Ferreira (Lisbon, PT)

Abstract Slides Video

Presentation thumbnail

Socioeconomic disparities in guideline directed medical therapy for HFrEF: a population-based cohort study using electronic health records (the Netherlands)

Ms J. van Eijk (Utrecht, NL)

Abstract Slides Video

Access the full session

Session thumbnail

Digitoxin and other therapeutic strategic advances

The Event

Event poster

Heart Failure 2025

19 May 2025 16:00 CET

You may be interested in

Congress Presentation

MRAs in heart failure - An individual patient data meta-analysis of randomised trials

Congress Presentation

Discussant review - MRAs in heart failure

Congress Presentation

Mineralocorticoid receptor antagonists in heart failure with mildly reduced and preserved ejection fraction: an updated systematic review and meta-analysis of randomized clinical trials

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources